Treatment by a specialist surgical neuro-oncologist does not provide any survival advantage for patients with a malignant glioma

British Journal of Neurosurgery

Volumn 12, Issue 1, 1998, Pages 29-32

  Latif, A Z B ^a   Signorini, D F ^a   Whittle, I R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Anaplastic astrocytoma; Glioblastoma; Oncologist; Surgery

Indexed keywords

ARTICLE; CANCER SURVIVAL; CASE MIX; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT OUTCOME;

ASTROCYTOMA; BRAIN NEOPLASMS; CLINICAL COMPETENCE; GLIOBLASTOMA; HUMANS; NEUROSURGERY; PATIENT CARE TEAM; PROPORTIONAL HAZARDS MODELS; SCOTLAND; SPECIALISM; SURVIVAL ANALYSIS;

EID: 0031881746     PISSN: 02688697     EISSN: None     Source Type: Journal    
DOI: 10.1080/02688699845474     Document Type: Article

References (19)

1. McArdle CS, Hole D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ 1991;302:1501-5.
2. Haglund MM, Berger MS, Shamseldin M, Lettich E, Ojemann GA. Cortical localisation of temporal lobe language sites in patients with gliomas. Neurosurgery 1994;34:567-76.
3. Davenport RJ, Dennis MS, Warlow CP. Effect of correcting outcome data for case mix: an example from stroke medicine. BMJ 1996;312:1503-5.
4. MRC Brain Tumour Working Party. Prognostic factors for high grade gliomas: development of a prognostic index. J Neurooncol 1990;9:47-55.
5. Fine HA. The basis for current treatment recommendations for malignant gliomas. J Neurooncol 1994;20:111-20.
6. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Cancer 1985;56:1106-11.
7. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg 1989;71:1-9.
8. Grambsch P, Themeau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika, 1994;81:515-26.
9. Chang CH, Horton J, Schoenfeld D, Salazar O, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant glioma. Cancer 1983;52:997-1007.
10. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumour Group. Evaluation of CCNU, VM-26 plus CCNU and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. J Neurosurg 1981;55:27-31.
11. Simpson JR, Horton J, Scott C, Curran WJ, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme, results from three consecutive radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239-44.
12. Jeremic B, Grujicic D, Antunovic V, Djuric L, et al. Influence of extent of surgery and tumour location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol 1994;21:177-85.
13. Kelly PJ. Volumetric stereotactical surgical resection of intra-axial brain mass lesions. Mayo Clin Proc 1988;63:1186-98.
14. Cabantog AM, Bernstein M. Complications of first craniotomy for intra-axial tumour. Can J Neurol Sci 1994;21:213-18.
15. Grant RG, Slattery J, Gregor A, Whittle IR. Recording neurological impairment in clinical trials of glioma. Neurooncol 1994;19:37-49.
16. Maurice-Williams R. The notes in the cupboard: the question of intellectual honesty in neurosurgery (Editorial). Br J Neurosurg 1997;11:277-9.
17. Rothwell P, Warlow CP. Is self-audit reliable? Lancet 1995;346:1623.
18. Thomson A-M, Taylor R, Fraser D, Whittle IR. Changes in language function following surgery for intracranial neoplasm; a prospective study. Br J Neurosurg 1994;8:263.
19. Weismann DE, Dufer D, Vogel V. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 1987;5:125-81.